Home » BAYER'S SCHERING BUY UNCONDITIONALLY CLEARED BY EU

BAYER'S SCHERING BUY UNCONDITIONALLY CLEARED BY EU

May 24, 2006

The European Commission said it has cleared the proposed acquisition of the German pharmaceutical company Schering AG by Bayer AG also of Germany. The commission said the activities of the parties are mainly complementary with the main overlaps in a few over-the-counter (OTC) and prescription antifungal markets.
Euro2Day

KEYWORDS FDAnews Drug Daily Bulletin

08Sep
Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections
15Sep
Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis
20Sep
Building a World-Class Pharmaceutical Advertising and Promotion Review Program
21Sep
The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval
22Sep
FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers
11Oct
1st Annual Quality Management vSummit

BAYER'S SCHERING BUY UNCONDITIONALLY CLEARED BY EU

Upcoming Events

Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

Building a World-Class Pharmaceutical Advertising and Promotion Review Program

The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

1st Annual Quality Management vSummit

Featured Products

FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

AngioDynamics Gets Expanded Clearance for Auryon Atherectomy System

Aura Biosciences Receives Fast Track Designation for Bladder Cancer Candidate

FDA Issues Update on Becton Dickinson’s Recall

FDA Grants Accelerated Approval to Enhertu for HER2-Mutant NSCLC

The Revised ICH E8: A Guide to New Clinical Trial Requirements